Drug
Pafolacianine clinical trials
Also written OTL38 and Cytalux.
- studies test it
- 12
- open now
- 5
- in phase 3
- 1
- first study started
- 2014
Keep track of what changes. Save the Pafolacianine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
12 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 3 |
| 2017 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 4
- Phase 3
- 1
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 9
On Target Laboratories, LLC (3) · University of Pennsylvania (2) · Indiana University (1) · Chandru Sundaram (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · John Waters (1) · Mayo Clinic (1) · Cedars-Sinai Medical Center (1)
Studies
Open first, then newest update. How each study uses Pafolacianine is read from its arms, and is right about nine times in ten.
Testing it · 12
- CYTALUX Dose Extension StudyNot yet recruitingPhase 4On Target Laboratories, LLCNCT07469202Written as CYTALUX (pafolacianine) injection
- Safety and Feasibility of Intraoperative Visualization With Cytalux in ChildrenRecruitingPhase 1Ann & Robert H Lurie Children's Hospital of ChicagoNCT06235125Written as Cytalux
- Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.RecruitingPhase 2John WatersNCT07039526Written as CYTALUX™ (pafolacianine) injection preoperatively
- An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid TumorsRecruitingPhase 3Mayo ClinicNCT06915727Written as Pafolacianine Sodium
- Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)RecruitingPhase 4Cedars-Sinai Medical CenterNCT07124351Written as CYTALUX™ (pafolacianine)
- CYTALUX™for the Intraoperative Imaging of Prostate CancerCompletedPhase 2Indiana UniversityNCT06434909Written as Cytalux™ (pafolacianine) for fluorescent imaging
- OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung NodulesCompletedPhase 2On Target Laboratories, LLCNCT02872701Written as OTL38 for Injection
- Intraoperative Imaging of Pulmonary Nodules by OTL38CompletedPhase 1University of PennsylvaniaNCT02602119Written as OTL38
- OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian CancerWithdrawnPhase 1Abramson Cancer Center at Penn MedicineNCT04941378Written as OTL38
- Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian CancerCompletedPhase 2On Target Laboratories, LLCNCT02317705Written as OTL38
- Intraoperative Folate Targeted Fluorescence in Renal Cell CarcinomaCompletedNot applicableChandru SundaramNCT02645409Written as OTL38
- Intraoperative Imaging of Pituitary Adenomas by OTLTerminatedPhase 1University of PennsylvaniaNCT02629549Written as OTL38
Given in every arm · 2 — Pafolacianine is usual care beside what is tested
- ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor TargetingCompletedPhase 3On Target Laboratories, LLCNCT04241315Written as OTL38 for Injection
- OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian CancerCompletedPhase 3On Target Laboratories, LLCNCT03180307Written as OTL38
As the comparator · 1 — what is tested is compared with Pafolacianine
Codes
What other systems call Pafolacianine · ClinicalTrials.gg INT001744
- MeSH (NLM) C000720187PafolacianineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) F7BD3Z4X8LPAFOLACIANINEConfirmed FDA, NLM, Wikidata
- RxNorm 2586857One source FDA
- Wikidata Q27277759pafolacianineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175834PafolacianineOne source FDA
- DrugBank DB15413One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720187 | Pafolacianine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | F7BD3Z4X8L | PAFOLACIANINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2586857 | — | One source FDA |
| Wikidata | Q27277759 | pafolacianine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175834 | Pafolacianine | One source FDA |
| DrugBank | DB15413 | — | One source Wikidata |
Also registered as pafolacianine sodium (UNII 4HUF3V875C · RxNorm 2586858).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.